At a glance
ClinicalIndex Comparison RecordN/ACompleted· 42,953 enrolled
Drug / intervention
Tiotropium bromide + Olodaterol +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effectiveness and Safety of Maintenance Treatment With Combination of Tiotropium and Olodaterol in Comparison to Maintenance Treatment With a Combination of Inhaled Corticosteroids and Long-acting β2 Agonists in COPD Patients
In Brief
An observational study evaluating Tiotropium bromide + Olodaterol and LABA/ICS for COPD. Completed, enrolled 42,953 participants across 1 site.
Detailed Summary
The primary objective is to compare the effectiveness of maintenance therapy initiation with the combination treatment Tiotropium and Olodaterol (Olo+Tio) compared with LABA/ICS combination in COPD as the time to the first COPD exacerbation. Secondary objectives are to compare patients treated with Tio+Olo and patients treated with LABA/ ICS combination.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCOPD
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2020202120222023202420252026
First PostedOct 2019
Enrollment StartNov 2019
Primary CompletionNov 2019
TodayJul 2026
First PostedOct 24, 2019
Enrollment StartNov 1, 2019
Primary CompletionNov 4, 2019
TodayJul 2, 2026
Enrollment to primary: 3 daysPosted 6.7 years ago
Interventions
Tiotropium bromide + Olodateroldrug
Tiotropium bromide + Olodaterol
LABA/ICSdrug
Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS)